Farshad Farzadfar

National and sub-national burden and trend of type 1 diabetes in 31 provinces of Iran, 1990-2019.

Bandarian F, Sharifnejad Tehrani Y, Peimani M, Namazi N, Saeedi Moghaddam S, Esmaeili S, Rashidi MM, Nasli Esfahani E, Masinaei M, Rezaei N, Rezaei N, Farzadfar F, Larijani B.

Sci Rep. 2023 Mar 14. 13(1):4210. PMID: 36918650

A 30-year trend of ischemic heart disease burden in a developing country; a systematic analysis of the global burden of disease study 2019 in Iran.

Koolaji S, Tehrani YS, Azadnajafabad S, Moghaddam SS, Shahin S, Ghamari A, Ahmadi N, Rezaei N, Keykhaei M, Tavolinejad H, Ghamari SH, Abbasi-Kangevari M, Rezaei N, Larijani B, Farzadfar F.

Int J Cardiol. 2023 Mar 08. PMID: 36898585

Trends of national and sub-national burden attributed to kidney dysfunction risk factor in Iran: 1990-2019.

Nejadghaderi SA, Saeedi Moghaddam S, Keykhaei M, Shobeiri P, Rezaei N, Rezaei N, Naghavi M, Larijani B, Farzadfar F.

Front Endocrinol (Lausanne). 2023. 14:1115833. PMID: 36923218

Effect of the chronic medication use on outcome measures of hospitalized COVID-19 patients: Evidence from big data.

Malekpour MR, Abbasi-Kangevari M, Shojaee A, Saeedi Moghaddam S, Ghamari SH, Rashidi MM, Namazi Shabestari A, Effatpanah M, Nasehi M, Rezaei M, Farzadfar F.

Front Public Health. 2023. 11:1061307. PMID: 36908454

Burden of tracheal, bronchus, and lung cancer in North Africa and Middle East countries, 1990 to 2019: Results from the GBD study 2019.

Khanmohammadi S, Saeedi Moghaddam S, Azadnajafabad S, Rezaei N, Esfahani Z, Rezaei N, Naghavi M, Larijani B, Farzadfar F.

Front Oncol. 2022. 12:1098218. PMID: 36844919

The incremental cost of implementing the world health organization Package of essential non-communicable (PEN) diseases interventions in Iran.

Azmin M, Mohebi F, Yoosefi M, Ahmadi N, Shirazi S, Modirian M, Farzadfar F.

PLOS Glob Public Health. 2023. 3(2):e0000449. PMID: 36962715

One-step versus two-step screening for diagnosis of gestational diabetes mellitus in Iranian population: A randomized community trial.

Ramezani Tehrani F, Rahmati M, Farzadfar F, Abedini M, Farahmand M, Hosseinpanah F, Hadaegh F, Torkestani F, Valizadeh M, Azizi F, Behboudi-Gandevani S.

Front Endocrinol (Lausanne). 2022. 13:1039643. PMID: 36818463

Inequalities in the prevalence, diagnosis awareness, treatment coverage and effective control of diabetes: a small area estimation analysis in Iran.

Perseh L, Peimani M, Ghasemi E, Nasli-Esfahani E, Rezaei N, Farzadfar F, Larijani B.

BMC Endocr Disord. 2023 Jan 18. 23(1):17. PMID: 36650506

Association of plasma acylcarnitines and amino acids with hypertension: A nationwide metabolomics study.

Arjmand B, Dehghanbanadaki H, Yoosefi M, Rezaei N, Mohammadi Fateh S, Ghodssi-Ghassemabadi R, Najjar N, Hosseinkhani S, Tayanloo-Beik A, Adibi H, Farzadfar F, Larijani B, Razi F.

PLoS One. 2023. 18(1):e0279835. PMID: 36649284

Physical activity pattern in Iran: Findings from STEPS 2021.

Nejadghaderi SA, Ahmadi N, Rashidi MM, Ghanbari A, Noori M, Abbasi-Kangevari M, Nasserinejad M, Rezaei N, Yoosefi M, Fattahi N, Ghasemi E, Farzi Y, Abdolhamidi E, Darman M, Djalalinia S, Farzadfar F.

Front Public Health. 2022. 10:1036219. PMID: 36684955